Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

Clinical trial NCT03546842 · COMPLETED

Trial details

NCT number: NCT03546842
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Papillomavirus Infections Uterine Cervical Neoplasms Vulvar Neoplasms Vaginal Neoplasms Adenocarcinoma in Situ Condylomata Acuminata

Start date: 2018-06-29
Primary completion: 2019-01-29
Enrollment: 201

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.